Upsher-Smith Laboratories announced the launch of Exemestane Tablets, 25 mg. The company recently received U.S. Food and Drug Administration (FDA) approval of its abbreviated new drug application (ANDA) for the product. Exemestane Tablets are equivalent (AB-rated) to the branded product, Aromasin.
The exemestane tablet market had U.S. sales of approximately $84 million for the 12 months ending August 31, 2017 according to IMS Health.
"We are pleased to offer physicians and patients a cost-effective alternative to Aromasin," said Rusty Field, President and CEO of Upsher-Smith. "The addition of Exemestane Tablets supports our Company's ongoing commitment to expanding our product portfolio and making quality, reasonably priced generics available to the most patients possible."